The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that have an activating HER2 (ERBB2) mutation, following platinum-based chemotherapy treatment with or without immunotherapy. This significant decision is backed by the positive outcomes of the DESTINY-Lung02 phase 2 trial, […]
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). Specifically designed for tumors with an activating HER2 (ERBB2) mutation, the drug aims to fill a significant gap in systemic therapy options following platinum-based chemotherapy. Enhertu’s EU […]
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with multiple HER2-expressing advanced solid tumours. These positive outcomes mark the successful achievement of two secondary endpoints of the trial. In the primary analysis, Enhertu […]
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer. The approval applies to patients who have undergone prior systemic therapy in a metastatic setting or experienced disease recurrence within six […]
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu (trastuzumab deruxtecan) for the treatment of a type of breast cancer patients. Enhertu has been approved as a monotherapy for the treatment of adult patients having unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast […]
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment of a type of metastatic breast cancer in adult patients. Enhertu is said to be a specifically engineered HER2-directed antibody drug conjugate (ADC). It is being co-developed and commercialized by […]
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric cancer. Enhertu is a HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo. According to AstraZeneca, the antibody drug conjugate delivered the desired tumor response in patients suffering […]